MicroRNA-126 and micro-/macrovascular complications of type 1 diabetes in the EURODIAB Prospective Complications Study

Acta Diabetologica

Volumn 54, Issue 2, 2017, Pages 133-139

  Barutta, Federica ^a   Bruno, Graziella ^a   Matullo, Giuseppe ^a,e   Chaturvedi, Nish ^b   Grimaldi, Serena ^a   Schalkwijk, Casper ^c   Stehouwer, Coen D ^c   Fuller, John H ^d   Gruden, Gabriella ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c MAASTRICHT UNIVERSITY   (Netherlands)

^d ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^e Human Genetic Foundation (HuGeF)   (Italy)

Author keywords

Complications; MicroRNAs; Retinopathy; Type 1 diabetes

Indexed keywords

HEMOGLOBIN A1C; MICRORNA 126; BIOLOGICAL MARKER; MICRORNA; MIRN126 MICRORNA, HUMAN;

ADULT; AGE; ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIABETIC ANGIOPATHY; DISEASE ASSOCIATION; DISEASE DURATION; FEMALE; GENE EXPRESSION PROFILING; HUMAN; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; MICROANGIOPATHY; POLYMERASE CHAIN REACTION; POPULATION BASED CASE CONTROL STUDY; PROLIFERATIVE RETINOPATHY; PROSPECTIVE STUDY; SEX; ADOLESCENT; BLOOD; CASE CONTROL STUDY; COMPLICATION; DIABETIC RETINOPATHY; MIDDLE AGED; RISK FACTOR;

ADOLESCENT; ADULT; BIOMARKERS; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 1; DIABETIC ANGIOPATHIES; DIABETIC RETINOPATHY; FEMALE; HUMANS; MALE; MICRORNAS; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 84989172620     PISSN: 09405429     EISSN: 14325233     Source Type: Journal    
DOI: 10.1007/s00592-016-0915-4     Document Type: Article

References (40)

1. He L, Hannon GJ (2004) MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 5:522–531
2. Filios SR, Shalev A (2015) β-Cell microRNAs: small but powerful. Diabetes 64:3631–3644
3. Beltrami C, Angelini TG, Emanueli C (2014) Noncoding RNAs in diabetes vascular complications. J Mol Cell Cardiol 89:42–50
4. Shantikumar S, Caporali A, Emanueli C (2012) Role of microRNAs in diabetes and its cardiovascular complications. Cardiovasc Res 93:583–593
5. Mitchell PS, Parkin RK, Kroh EM et al (2008) Circulating miRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 105:10513–10518
6. Tanaka M, Oikawa K, Takanashi M et al (2009) Down-regulation of miR-92 in human plasma is a novel marker for acute leukemia patients. PLoS ONE 4:e5532
7. Laterza OF, Lim L, Garrett-Engele PW et al (2009) Plasma miRNAs as sensitive and specific biomarkers of tissue injury. Clin Chem 55:1977–1983
8. McManus DD, Ambros V (2011) Circulating miRNAs in cardiovascular disease. Circulation 124:1908–1910
9. Nielsen LB, Wang C, Sørensen K, et al (2012) Circulating levels of microRNA from children with newly diagnosed type 1 diabetes and healthy controls: evidence that miR-25 associates to residual beta-cell function and glycaemic control during disease progression. Exp Diabetes Res 2012:896362. doi:10.1155/2012/896362
10. Zampetaki A, Kiechl S, Drozdov I et al (2010) Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes. Circ Res 107:810–817
11. Zampetaki A, Willeit P, Burr S et al (2016) Angiogenic microRNAs linked to incidence and progression of diabetic retinopathy in type 1 diabetes. Diabetes 65:216–227
12. Pezzolesi MG, Satake E, McDonnell KP et al (2015) Circulating TGF-β1-regulated miRNAs and the risk of rapid progression to ESRD in type 1 diabetes. Diabetes 64:3285–3293
13. The EURODIAB IDDM Complications Study Group (1994) Microvascular and acute complications in IDDM patients: the EURODIAB IDDM complications study. Diabetologia 3:278–285
14. Chaturvedi N, Sjoelie AK, Porta M et al (2001) EURODIAB prospective complications study: markers of insulin resistance are strong risk factors for retinopathy incidence in type 1 diabetes. Diabetes Care 24:284–289
15. Schram MT, Chaturvedi N, Schalkwijk CG et al (2005) EURODIAB prospective complications study group. Markers of inflammation are cross-sectionally associated with microvascular complications and cardiovascular disease in type 1 diabetes: the EURODIAB prospective complications study. Diabetologia 48:370–378
16. Gruden G, Bruno G, Chaturvedi N et al (2009) EURODIAB prospective complications study group. ANTI-HSP60 and ANTI-HSP70 antibody levels and micro/macrovascular complications in type 1 diabetes: the EURODIAB study. J Intern Med 266:527–536
17. Gruden G, Bruno G, Chaturvedi N et al (2008) EURODIAB prospective complications study group. Serum heat shock protein 27 and diabetes complications in the EURODIAB prospective complications study: a novel circulating marker for diabetic neuropathy. Diabetes 57:1966–1970
18. Burt D, Bruno G, Chaturvedi N et al (2009) Anti-heat shock protein 27 antibody levels and diabetes complications in the EURODIAB study. Diabetes Care 32:1269–1271
19. Chaturvedi N, Schalkwijk CG, Abrahamian H et al (2002) EURODIAB prospective complications study group. Circulating and urinary transforming growth factor beta1, Amadori albumin, and complications of type 1 diabetes: the EURODIAB prospective complications study. Diabetes Care 25:2320–2327
20. Giunti S, Bruno G, Lillaz E et al (2007) EURODIAB IDDM complications study group. Incidence and risk factors of prolonged QTc interval in type 1 diabetes: the EURODIAB prospective complications study. Diabetes Care 30:2057–2063
21. Levey AS, Bosch JP, Lewis JB et al (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in renal disease study group. Ann Intern Med 130:461–470
22. Harris TA, Yamakuchi M, Ferlito M et al (2008) MicroRNA-126 regulates endothelial expression of vascular cell adhesion molecule 1. Proc Natl Acad Sci USA 105:1516–1521
23. Martin MM, Lee EJ, Buckenberger JA et al (2006) MicroRNA-155 regulates human angiotensin II type 1 receptor expression in fibroblasts. J Biol Chem 281:18277–18284
24. Martin MM, Buckenberger JA, Jiang J et al (2007) The human angiotensin II type 1 receptor +1166 A/C polymorphism attenuates microRNA-155 binding. J Biol Chem 282:24262–24269
25. Barutta F, Tricarico M, Corbelli A et al (2013) Urinary exosomal microRNAs in incipient diabetic nephropathy. PLoS ONE 8:e73798
26. Fichtlscherer S, De Rosa S, Fox H et al (2010) Circulating microRNAs in patients with coronary artery disease. Circ Res 107:677–684
27. Wang C, Wan S, Yang T et al (2016) Increased serum microRNAs are closely associated with the presence of microvascular complications in type 2 diabetes mellitus. Sci Rep 6:20032
28. Spinetti G, Fortunato O, Caporali A et al (2013) MicroRNA-15a and microRNA-16 impair human circulating proangiogenic cell functions and are increased in the proangiogenic cells and serum of patients with critical limb ischemia. Circ Res 112:335–346
29. Wang F, Long G, Zhao C et al (2013) Plasma microRNA-133a is a new marker for both acute myocardial infarction and underlying coronary artery stenosis. J Transl Med 11:222
30. Afanasyeva EA, Mestdagh P, Kumps C et al (2011) MicroRNA miR-885-5p targets CDK2 and MCM5, activates p53 and inhibits proliferation and survival. Cell Death Differ 18:974–984
31. van Solingen C, Bijkerk R, de Boer HC et al (2015) The role of microRNA-126 in vascular homeostasis. Curr Vasc Pharmacol 13:341–351
32. Asgeirsdóttir SA, van Solingen C, Kurniati NF et al (2012) MicroRNA-126 contributes to renal microvascular heterogeneity of VCAM-1 protein expression in acute inflammation. Am J Physiol Renal Physiol 302:F1630–F1639
33. Jansen F, Yang X, Hoelscher M et al (2013) Endothelial microparticle-mediated transfer of MicroRNA-126 promotes vascular endothelial cell repair via SPRED1 and is abrogated in glucose-damaged endothelial microparticles. Circulation 128:2026–2038
34. Zhang T, Lv C, Li L et al (2013) Plasma miR-126 is a potential biomarker for early prediction of type 2 diabetes mellitus in susceptible individuals. Biomed Res Int 2013:761617
35. Zhang Y, Wang X, Xu B et al (2013) Epigenetic silencing of miR-126 contributes to tumor invasion and angiogenesis in colorectal cancer. Oncol Rep 30:1976–1984
36. Chen H, Li L, Wang S et al (2014) Reduced miR-126 expression facilitates angiogenesis of gastric cancer through its regulation on VEGF-A. Oncotarget 5:11873–11885
37. Ye P, Liu J, He F et al (2013) Hypoxia-induced deregulation of miR-126 and its regulative effect on VEGF and MMP-9 expression. Int J Med Sci 11:17–23
38. van Solingen C, de Boer HC, Bijkerk R et al (2011) MicroRNA-126 modulates endothelial SDF-1 expression and mobilization of Sca-1(+)/Lin(-) progenitor cells in ischaemia. Cardiovasc Res 92:449–455
39. Butler JM, Guthrie SM, Koc M et al (2005) SDF-1 is both necessary and sufficient to promote proliferative retinopathy. J Clin Invest 115:86–93
40. McManus DD, Freedman JE (2015) MicroRNAs in platelet function and cardiovascular disease. Nat Rev Cardiol 12:711–717